bryostatin Report issue

Small molecule Experimental
AACT DrugBank PubChem

Active Ingredient History

NOW
  • Now
Bryostatins are a group of macrolide lactones from the marine organism Bugula neritina that were first collected and provided to JL Hartwell’s anticancer drug discovery group at the National Cancer Institute (NCI) by Jack Rudloe. Bryostatins are potent modulators of protein kinase C. They have been studied in clinical trials as anti-cancer agents, as anti-AIDS/HIV agents and in people with Alzheimer's disease.   Wikipedia

Chemistry

  • SMILES: CCC/C=C/C=C/C(=O)O[C@H]1/C(=C/C(=O)OC)C[C@H]2C[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H]3C[C@H](OC(C)=O)C(C)(C)[C@](O)(C[C@@H]4C/C(=C/C(=O)OC)C[C@H](/C=C/C(C)(C)[C@]1(O)O2)O4)O3
  • InChIKey: MJQUEDHRCUIRLF-TVIXENOKSA-N
  • Mol. Mass: 905.04
  • ALogP: 4.28
  • ChEMBL Molecule:
    bryostatin 1  
More Chemistry

Pharmacology

Alternative names

bryostatin | bryostatin 1 | bryostatin-1

Organizations (31)

Research & Development (31)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (38)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (38)


 

Alzheimer Disease (Phase 2)

Anemia, Refractory (Phase 1)

Breast Neoplasms (Phase 2)

Burkitt Lymphoma (Phase 1)

Carcinoma, Renal Cell (Phase 2)

Colorectal Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Hamartoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hemoglobinuria, Paroxysmal (Phase 1)

HIV Infections (Phase 1)

Intestinal Neoplasms (Phase 1)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia-Lymphoma, Adult T-Cell (Phase 1)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, AIDS-Related (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Melanoma (Phase 1)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Thrombocytopenia (Phase 1)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 43
  • # of Trial Organizations: 31

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue